加载中
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
前收盘价
US$13.89
+US$0.15 · +1.09%
盘后
US$13.89
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
日内区间
当前US$13.89
52周区间
当前US$13.89
盘中时间采用ET。市场数据可能有所延迟。
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
日内区间
当前US$13.89
52周区间
当前US$13.89
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 635.9万 USD | — | — | — |
| 销货成本 | — | — | — | 69.5万 USD | 96万 USD |
| 毛利 | — | 635.9万 USD | — | −69.5万 USD | −96万 USD |
| 研究与开发 | 305.6万 USD | 357.7万 USD | 859.8万 USD | 2372.7万 USD | 2289.9万 USD |
| 销售、一般及管理费用 | 338.2万 USD | 525万 USD | 869万 USD | 999.7万 USD | 1848.9万 USD |
| 营业费用 | 643.8万 USD | 882.7万 USD | 1728.8万 USD | 3372.4万 USD | 4138.8万 USD |
| 利息收入 | 3.3万 USD | 2.7万 USD | 25.2万 USD | 27.4万 USD | 8000 USD |
| 利息支出 | 104.9万 USD | 114.4万 USD | 115.1万 USD | 194.9万 USD | 125.9万 USD |
| 折旧和摊销 | — | 16.4万 USD | 80.9万 USD | 69.5万 USD | 96万 USD |
| 营业利润 | −643.8万 USD | −246.8万 USD | −1728.8万 USD | −3441.9万 USD | −4234.8万 USD |
| 净利润 | −599.5万 USD | −314.3万 USD | −1705.4万 USD | −3606.5万 USD | −6672.7万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$37.67
上涨空间 171.20%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年6月1日 | 1:11 | — | — |
股票拆分 | 2022年12月2日 | 1:40 | — | — |
股票拆分 | 2017年12月20日 | 1:20 | — | — |
股票拆分 | 2013年10月21日 | 1:100 | — | — |
股票拆分 | 1999年10月25日 | 2:1 | — | — |
已生效 2026年6月1日
1:11
已生效 2022年12月2日
1:40
已生效 2017年12月20日
1:20
已生效 2013年10月21日
1:100
已生效 1999年10月25日
2:1
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
